TNF and inflammatory bowel disease: Data supporting the role of anti-TNF agents includes resolution of arthritis in 75% of patients treated with adalimumab in an open label phase IIIb trial, a 73% response rate to anti-TNF therapy in the Swiss IBD cohort study, and statistically significant improvement in articular symptoms in a cohort of 24 patients with CD [41–44].